Osilodrostat 1mg    (DrugBank: Osilodrostat)

1 disease
IDDisease name (Link within this page)Number of trials
75Cushing disease18

75. Cushing disease    [ 191 clinical trials,   172 drugs,   (DrugBank: 48 drugs),   61 drug target genes,   121 drug target pathways]
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
18 / 191 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-001522-25-IT
(EUCTR)
20/01/202028/04/2020A study of osilodrostat in children and adolescents with Cushing's diseaseA phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease Cushing's disease
MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy
2EUCTR2017-002840-34-NL
(EUCTR)
14/11/201931/07/2019Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat studyAn open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat Cushing's syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Recordati AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 2United States;Portugal;Thailand;Spain;Costa Rica;Turkey;Austria;Russian Federation;Italy;India;France;Canada;Argentina;Poland;Belgium;Brazil;Bulgaria;Netherlands;Germany;Japan;China;Korea, Republic of
3EUCTR2018-001522-25-ES
(EUCTR)
02/10/201926/07/2019A study of osilodrostat in children and adolescents with Cushing's diseaseA phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease Cushing's disease
MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Novartis Farmacéutica, S.A.NULLNot RecruitingFemale: yes
Male: yes
12Phase 2United States;Slovenia;Belgium;Spain;Bulgaria;Italy;United Kingdom
4EUCTR2018-001522-25-BG
(EUCTR)
04/07/201926/03/2019A study of osilodrostat in children and adolescents with Cushing's diseaseA phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease Cushing's disease
MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Recordati AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy
5EUCTR2017-002840-34-BG
(EUCTR)
18/06/201907/09/2018Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat studyAn open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat Cushing's syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Recordati AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 2United States;Portugal;Greece;Costa Rica;Spain;Thailand;Russian Federation;Colombia;Italy;Switzerland;India;France;Netherlands;China;Korea, Republic of;Turkey;Austria;United Kingdom;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2018-001522-25-BE
(EUCTR)
05/06/201930/04/2019A study of osilodrostat in children and adolescents with Cushing's diseaseA phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease Cushing's disease
MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy
7EUCTR2018-001522-25-SI
(EUCTR)
10/05/201916/10/2018A study of osilodrostat in children and adolescents with Cushing's diseaseA phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease Cushing's disease
MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Recordati AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2United States;Slovenia;Spain;Belgium;Bulgaria;United Kingdom;Italy
8EUCTR2018-001522-25-GB
(EUCTR)
19/03/201927/09/2018A study of osilodrostat in children and adolescents with Cushing's diseaseA phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disease Cushing's disease
MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: OSILODROSTAT
Recordati AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2United States;Slovenia;Spain;Belgium;Bulgaria;Italy;United Kingdom
9EUCTR2017-002840-34-ES
(EUCTR)
31/10/201811/07/2018Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat studyAn open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat Cushing's syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Novartis Farmacéutica, S.ANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 2United States;Portugal;Greece;Thailand;Spain;Costa Rica;Russian Federation;Colombia;Switzerland;Italy;India;France;Netherlands;China;Korea, Republic of;Turkey;Austria;United Kingdom;Canada;Argentina;Brazil;Belgium;Poland;Bulgaria;Germany;Japan
10EUCTR2017-002840-34-AT
(EUCTR)
03/08/201822/05/2018Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat studyAn open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat Cushing's syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Recordati AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 2United States;Portugal;Thailand;Spain;Costa Rica;Turkey;Austria;Russian Federation;Italy;India;France;Canada;Argentina;Poland;Belgium;Brazil;Bulgaria;Netherlands;Germany;China;Japan;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2017-002840-34-DE
(EUCTR)
13/07/201829/05/2018Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat studyAn open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat Cushing's syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Recordati AGNULLNot RecruitingFemale: yes
Male: yes
200Phase 2United States;Portugal;Thailand;Spain;Costa Rica;Turkey;Austria;Russian Federation;Italy;India;France;Canada;Argentina;Poland;Belgium;Brazil;Bulgaria;Netherlands;Germany;China;Japan;Korea, Republic of
12EUCTR2014-004092-23-PL
(EUCTR)
08/09/201625/07/2016Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseA Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing’s disease - LINC-4 Cushing's disease
MedDRA version: 20.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 20mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Novartis Pharma Services AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
69Phase 3Portugal;United States;Greece;Spain;Thailand;Costa Rica;Turkey;Russian Federation;Switzerland;Canada;Poland;Belgium;Brazil;Denmark;China
13EUCTR2014-004092-23-GR
(EUCTR)
05/07/201611/05/2016Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseA Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing’s disease - LINC-4 Cushing's disease
MedDRA version: 19.0;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 20mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Novartis Pharma Services AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
69Phase 3United States;Greece;Poland;Brazil;Belgium;Thailand;Spain;Turkey;Denmark;Russian Federation;Switzerland
14EUCTR2014-004092-23-ES
(EUCTR)
29/04/201618/03/2016Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseA Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing?s disease - LINC-4 Cushing's disease
MedDRA version: 18.1;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 20mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Novartis Farmacéutica, S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
69Phase 3United States;Greece;Poland;Brazil;Belgium;Thailand;Spain;Turkey;Denmark;Russian Federation;Switzerland
15EUCTR2013-004766-34-NL
(EUCTR)
04/02/201521/08/2014Safety and efficacy of osilodrostat (LCI699) for the treatment of patients with Cushing's diseaseA Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing’s disease Cushing's disease;Therapeutic area: Diseases [C] - Cancer [C04]Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 20mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
132Phase 3United States;Thailand;Spain;Turkey;Austria;Russian Federation;Colombia;United Kingdom;Italy;India;France;Canada;Argentina;Australia;Bulgaria;Netherlands;Germany;China;Japan;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2013-004766-34-GB
(EUCTR)
20/11/201422/07/2014Safety and efficacy of LCI699 for the treatment of patients with Cushing's diseaseA Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing’s disease Cushing's disease;Therapeutic area: Diseases [C] - Cancer [C04]Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 20mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
132Phase 3United States;Spain;Thailand;Turkey;Austria;Russian Federation;Colombia;Italy;United Kingdom;India;France;Canada;Argentina;Australia;Bulgaria;Netherlands;Germany;Japan;China;Korea, Republic of
17EUCTR2013-004766-34-DE
(EUCTR)
06/10/201429/07/2014Safety and efficacy of osilodrostat (LCI699) for the treatment of patients with Cushing's diseaseA Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing’s disease Cushing's disease;Therapeutic area: Diseases [C] - Cancer [C04]Product Name: osilodrostat 1mg
Product Code: LCI699, 1 mg
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 5mg
Product Code: LCI699, 5 mg
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 10mg
Product Code: LCI699, 10 mg
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Product Name: osilodrostat 20mg
Product Code: LCI699, 20 mg
INN or Proposed INN: osilodrostat
Other descriptive name: LCI699
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
132Phase 3United States;Thailand;Spain;Turkey;Austria;Russian Federation;Colombia;United Kingdom;Italy;India;France;Canada;Argentina;Australia;Bulgaria;Netherlands;Germany;China;Japan;Korea, Republic of
18EUCTR2017-002840-34-PL
(EUCTR)
05/03/2020Roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat studyAn open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat Cushing's syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: osilodrostat 1mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 5mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Product Name: osilodrostat 10mg
Product Code: LCI699
INN or Proposed INN: osilodrostat
Recordati AGNULLNAFemale: yes
Male: yes
200Phase 2United States;Portugal;Thailand;Spain;Costa Rica;Turkey;Austria;Russian Federation;Italy;India;France;Canada;Argentina;Poland;Belgium;Brazil;Bulgaria;Netherlands;Germany;Japan;China;Korea, Republic of